» Articles » PMID: 32774416

Shenzhiling Oral Liquid Protects STZ-Injured Oligodendrocyte Through PI3K/Akt-mTOR Pathway

Overview
Date 2020 Aug 11
PMID 32774416
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

White matter degeneration and demyelination are nonnegligible pathological manifestations of Alzheimer's disease (AD). The damage of myelin sheath consisting of oligodendrocytes is the basis of AD's unique early lesions. Shenzhiling oral liquid (SZL) was the effective Chinese herbal compound approved by the Food and Drug Administration (FDA) for the treatment of AD in China, which plays the exact therapeutic role in clinical AD patients. However, its molecular mechanism remains unclear to date. For this purpose, an in vitro mode of streptozotocin- (STZ-) induced rat oligodendrocyte OLN-93 cell injury was established to mimic the pathological changes of myelin sheath of AD and investigate the mechanism of SZL protecting injured OLN-93 cell. The results showed that STZ can decrease cell viability and downregulate the activity of PI3K/Akt-mTOR signalling pathway and the expression of myelin sheath-related proteins (MBP, MOG, and PLP) in OLN-93 cells. Both SZL-medicated serum and donepezil (positive control) can protect cells from STZ-caused damage. SZL-medicated serum increased OLN-93 cell viability in a dose- and time-dependent manner and enhanced the activity of PI3K/Akt-mTOR signalling pathway. The inhibitor of PI3K (LY294002) inhibited the protective effect of SZL-medicated serum on the STZ-injured OLN-93 cells. Furthermore, rapamycin, the inhibitor of mTOR, inhibited the promotion of cell viability and upregulation of p-mTOR and MBP caused by SZL-medicated serum. In conclusion, our data indicate that SZL plays its therapeutic role on AD by promoting PI3K/Akt-mTOR signalling pathway of oligodendrocytes. Thus, the present study may facilitate the therapeutic research of AD.

Citing Articles

White Matter Injury in Central Nervous System Disorders.

Zheng L, Wang X, Li P, Hao Y, Zhang H, Chen H Neuropsychiatr Dis Treat. 2025; 21:107-114.

PMID: 39877856 PMC: 11774249. DOI: 10.2147/NDT.S498660.


Shen Zhi Ling oral liquid improve neuroinflammation against Alzheimer's disease via the PI3K/Akt pathway.

Qin G, Cui W, Song R 3 Biotech. 2025; 15(1):29.

PMID: 39760003 PMC: 11695662. DOI: 10.1007/s13205-024-04182-5.


Investigating the therapeutic effects of Shenzhiling oral liquid on Alzheimer's disease: a network pharmacology and experimental approach.

Qin G, Song R, Sun J, Chen B, Liu Z, Han L 3 Biotech. 2024; 15(1):14.

PMID: 39703418 PMC: 11652558. DOI: 10.1007/s13205-024-04181-6.


Comprehensive analysis of mRNAs in the cerebral cortex in APP/PS1 double-transgenic mice with Alzheimer's disease based on high-throughput sequencing of N4-acetylcytidine.

Ma Y, Fan C, Wang Y, Li W, Jiang H, Yang W Funct Integr Genomics. 2023; 23(3):267.

PMID: 37548859 DOI: 10.1007/s10142-023-01192-z.


Myelin sheath injury and repairment after subarachnoid hemorrhage.

Chen M, Guo P, Ru X, Chen Y, Zuo S, Feng H Front Pharmacol. 2023; 14:1145605.

PMID: 37077816 PMC: 10106687. DOI: 10.3389/fphar.2023.1145605.


References
1.
Salkovic-Petrisic M, Knezovic A, Hoyer S, Riederer P . What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm (Vienna). 2012; 120(1):233-52. DOI: 10.1007/s00702-012-0877-9. View

2.
Biswas J, Gupta S, Verma D, Singh S . Streptozotocin alters glucose transport, connexin expression and endoplasmic reticulum functions in neurons and astrocytes. Neuroscience. 2017; 356:151-166. DOI: 10.1016/j.neuroscience.2017.05.018. View

3.
Bartzokis G, Cummings J, Sultzer D, Henderson V, Nuechterlein K, Mintz J . White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol. 2003; 60(3):393-8. DOI: 10.1001/archneur.60.3.393. View

4.
Wong J, Halliday G, Kim W . Exploring myelin dysfunction in multiple system atrophy. Exp Neurobiol. 2014; 23(4):337-44. PMC: 4276804. DOI: 10.5607/en.2014.23.4.337. View

5.
Imamura O, Arai M, Dateki M, Ogata T, Uchida R, Tomoda H . Nicotinic acetylcholine receptors mediate donepezil-induced oligodendrocyte differentiation. J Neurochem. 2015; 135(6):1086-98. DOI: 10.1111/jnc.13294. View